Colorectal Cancer

- 3rd most common cancer in men and women in US
- 2nd leading cause of cancer death for men and women combined
- 5 year relative survival rate at time of diagnosis
  - 90% survival when diagnosed at stage I
  - 11% survival when diagnosed at stage IV (metastatic)
  - Only 40% of patients are diagnosed at stage I
- Enhanced screening efforts (guaiac-based fecal occult blood test – gFOBT – and colonoscopies) have led to decreased overall mortality rates in CRC, but 45% of population is not compliant with current screening guidelines
  - More user friendly screening platforms are required to enhance patient compliance with screening guidelines

Liquid Biopsies



BLOOD PLASMA
OR SERUM SAMPLE


OpenTrials
All the Data, on All the Trials, Linked
Login / Register
About
Patients
Researchers
Transparency
For researchers
Mertrazine and Cobazol to Treat Major Depression
XML
OpenTrials › For Researchers › Depression › Mertrazine and Cobazol
Overview
Condition: Major Depression
Teatment: Mertrazine, Cobazol
June 2004 - March 2010
218 Participants
Men and women
Aged 18-65
Registries
ClinicalTrials.gov
BioMet Inc
Add another
Regulatory documents
CSR
EPAR segment
Add another
Paperwork
Blank consent form
Patient information sheet
Blank case report form
Protocol
Statistical analysis plan
Lay summary
Ethics/IRB Approval
Add another
Papers
Results paper
Protocol paper
Add another
Structured data
ClinicalTrials.gov results
SRDR from AHRQ
Add another
Methodological rigour
The methodological rigour of this trial was scored in a systematic review in
Conducted in
Maryland, USA

OpenTrials API



Initial Data Exploration









Colorectal AND Bevacizumab



Status	Max Age	Min Age	Sample Size	Number of Countries	Pharmaceutical	Other	Surgical
Complete	99	18	1226	28	1	2	0
Terminated	99	18	8	1	0	2	0

KNN (K=10)





Boosted trees





RUSboosted trees